Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA5218653
Max Phase: Preclinical
Molecular Formula: C70H105IN24O21S4
Molecular Weight: 1873.93
Associated Items:
ID: ALA5218653
Max Phase: Preclinical
Molecular Formula: C70H105IN24O21S4
Molecular Weight: 1873.93
Associated Items:
Canonical SMILES: C[C@@H](O)[C@@H]1NC(=O)[C@H]2NC(=O)[C@H](NC(=O)CN)CSSC[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H]3CCCN3C(=O)[C@H](CC(=O)O)NC1=O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](Cc1ccc(O)c(I)c1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@H](Cc1ccc(O)cc1)C(=O)N[C@H](CCCNC(=N)N)C(=O)O)CSSC2(C)C
Standard InChI: InChI=1S/C70H105IN24O21S4/c1-32(96)52-63(112)90-43(27-51(101)102)65(114)95-23-7-11-47(95)62(111)86-38(9-5-21-81-68(76)77)55(104)91-45-30-118-117-29-44(83-50(100)28-72)61(110)94-53(64(113)93-52)70(2,3)120-119-31-46(60(109)89-41(25-33-12-15-35(97)16-13-33)58(107)87-40(66(115)116)10-6-22-82-69(78)79)92-56(105)39(17-19-49(73)99)85-57(106)42(26-34-14-18-48(98)36(71)24-34)88-54(103)37(84-59(45)108)8-4-20-80-67(74)75/h12-16,18,24,32,37-47,52-53,96-98H,4-11,17,19-23,25-31,72H2,1-3H3,(H2,73,99)(H,83,100)(H,84,108)(H,85,106)(H,86,111)(H,87,107)(H,88,103)(H,89,109)(H,90,112)(H,91,104)(H,92,105)(H,93,113)(H,94,110)(H,101,102)(H,115,116)(H4,74,75,80)(H4,76,77,81)(H4,78,79,82)/t32-,37+,38+,39+,40-,41-,42+,43+,44-,45+,46+,47+,52+,53-/m1/s1
Standard InChI Key: LBCONOSZVXIZDN-VVHDWSLVSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 1873.93 | Molecular Weight (Monoisotopic): 1872.5814 | AlogP: | #Rotatable Bonds: |
Polar Surface Area: | Molecular Species: | HBA: | HBD: |
#RO5 Violations: | HBA (Lipinski): | HBD (Lipinski): | #RO5 Violations (Lipinski): |
CX Acidic pKa: | CX Basic pKa: | CX LogP: | CX LogD: |
Aromatic Rings: | Heavy Atoms: | QED Weighted: | Np Likeness Score: |
1. Gajewiak J, Christensen SB, Dowell C, Hararah F, Fisher F, Huynh PN, Olivera BM, McIntosh JM.. (2021) Selective Penicillamine Substitution Enables Development of a Potent Analgesic Peptide that Acts through a Non-Opioid-Based Mechanism., 64 (13.0): [PMID:34142837] [10.1021/acs.jmedchem.1c00512] |
Source(1):